Clinical Trials for Denali Therapeutics

Explore 7 clinical trials worldwide

Showing 1-7 of 7 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Denali Therapeutics

Clinical Trials (7)

NCT06602193
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
PHASE2Recruiting
50 participants
Started: Oct 24, 2024 · Completed: Feb 28, 2028
1 condition2 sponsors16 locations
NCT06181136
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
PHASE1/PHASE2Active, not recruiting
20 participants
Started: Dec 7, 2023 · Completed: Aug 31, 2028
1 condition1 sponsor4 locations
NCT06075537
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
PHASE2/PHASE3Enrolling by invitation
99 participants
Started: Sep 20, 2023 · Completed: Jun 30, 2027
1 condition1 sponsor21 locations
NCT05371613
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
PHASE2/PHASE3Recruiting
63 participants
Started: Jul 21, 2022 · Completed: Dec 31, 2027
1 condition1 sponsor32 locations
NCT05348785
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
PHASE2Active, not recruiting
650 participants
Started: Apr 19, 2022 · Completed: Mar 9, 2026
1 condition2 sponsors113 locations
NCT05262023
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
PHASE1/PHASE2Recruiting
106 participants
Started: Feb 1, 2022 · Completed: Nov 30, 2028
1 condition2 sponsors32 locations
NCT04251026
A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome
PHASE1/PHASE2Active, not recruiting
47 participants
Started: Jul 16, 2020 · Completed: Feb 28, 2031
1 condition1 sponsor7 locations